$3.77
7.71% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Agenus Inc. Stock price

$3.50
+0.19 5.74% 1M
-1.74 33.21% 6M
+0.76 27.74% YTD
-9.15 72.32% 1Y
-43.41 92.54% 3Y
-68.53 95.14% 5Y
-86.58 96.11% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.01 0.28%
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Key metrics

Market capitalization $82.11m
Enterprise Value $478.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.98
P/S ratio (TTM) P/S ratio 0.51
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 59.00%
Revenue (TTM) Revenue $160.43m
EBIT (operating result TTM) EBIT $-100.80m
Free Cash Flow (TTM) Free Cash Flow $-170.79m
Cash position $44.78m
EPS (TTM) EPS $-11.00
P/E forward negative
P/S forward 0.77
EV/Sales forward 4.50
Short interest 12.54%
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Agenus Inc. forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Agenus Inc. forecast:

Buy
20%
Hold
80%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
160 160
59% 59%
100%
- Direct Costs 16 16
24% 24%
10%
145 145
80% 80%
90%
- Selling and Administrative Expenses 42 42
33% 33%
26%
- Research and Development Expense 188 188
15% 15%
117%
-86 -86
58% 58%
-53%
- Depreciation and Amortization 15 15
49% 49%
10%
EBIT (Operating Income) EBIT -101 -101
53% 53%
-63%
Net Profit -228 -228
16% 16%
-142%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Business Wire
7 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas. These findings further reinforce the consistency of the BOT/BAL combination, which has...
Neutral
Business Wire
14 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. Data from five presentations underscore the transformative potential of BOT/BAL across multiple lines of therapy in colorectal canc...
Neutral
Business Wire
about 2 months ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium. The conference will take place on January 23-25, 2025, in ...
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 389
Founded 1994
Website www.agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today